Search Results - "Svarovskaia, E.S"

P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks by Doehle, B.P, Svarovskaia, E.S, Chodavarapu, K, McNally, J, Pianko, S, Roberts, S.K, Brainard, D.M, Miller, M.D, Mo, H

Get full text

Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks by Gane, E, Svarovskaia, E.S, Dvory-Sobol, H, Hyland, R.H, Stamm, L.M, Brainard, D.M, Miller, M.D, Mo, H, Schwabe, C, Stedman, C.A

Get full text

P1242 RESISTANCE ANALYSIS OF HCV GENOTYPE 1 INFECTED PATIENTS TREATED WITH SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR THE NS5B NONNUCLEOSIDE INHIBITOR GS-9669: THE ELECTRON STUDY by Svarovskaia, E.S, Martin, R, Gontcharova, V, Hyland, R.H, Gane, E.J, Stedman, C.A, Symonds, W.T, Miller, M.D, Mo, H

Get full text

P1229 LOW PERSISTENCE OF RESISTANCE-ASSOCIATED VARIANTS AFTER 3 DAYS OF MONOTHERAPY WITH NS5B NNI SITE II INHIBITOR GS-9669 IN GENOTYPE 1 HCV PATIENTS by Dvory-Sobol, H, Gontcharova, V, Martin, R, Lawitz, E.J, McHutchison, J, Svarovskaia, E.S, Miller, M.D, Mo, H

Get full text

P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV by Sarrazin, C, Dvory-Sobol, H, Svarovskaia, E.S, Doehle, B, Martin, R, Zeuzem, S, Lawitz, E, Hyland, R, Pang, P.S, Knox, S, Gane, E, Reddy, R, Afdhal, N, Mizokami, M, Omata, M, Miller, M.D, Mo, H, Bourlière, M

Get full text

1193 RESISTANCE ANALYSES USING DEEP AND POPULATION SEQUENCING AFTER 3 DAY MONOTHERAPY WITH GS-9669, A NOVEL NON-NUCLEOSIDE NS5B INHIBITOR IN GENOTYPE 1 HCV PATIENTS by Dvory-Sobol, H, Svarovskaia, E.S, Gontcharova, V, Rossi, S, Lawitz, E.J, Miller, M.D, Mo, H

Get full text

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY by Kowdley, K.V, Stuart, G.C, Reddy, R.K, Rossaro, L, Bernstein, D.E, An, D, Svarovskaia, E.S, Hyland, R.H, Pang, P.S, Symonds, W.T, Mchutchison, J.G, Muir, A.J, Pockros, P.J, Pound, D, Fried, M.W

Get full text

1241 ABUNDANT MINORITY DRUG-RESISTANT NS3 MUTANTS DETECTED BY DEEP SEQUENCING IN HCV PATIENTS AS EARLY AS 24 HOURS AFTER INITIATING ANTIVIRAL TREATMENT by Svarovskaia, E.S, Martin, R, Miller, M.D, Mo, H

Get full text

1175 IN-VITRO FITNESS AND RESISTANCE ANALYSES OF NS3 MUTANTS DETECTED BY POPULATION AND DEEP SEQUENCING IN HCV PATIENTS FROM PHASE I STUDIES OF GS-9451 AND GS-9256 by Dvory-Sobol, H, Schwartz, T, Han, B, Worth, A, Rajyaguru, S, Svarovskaia, E.S, Miller, M.D, Mo, H

Get full text

THU-281 - Emergence and long-term persistence of NS3, NS5A, and NS5B resistance associated substitutions after treatment with direct-acting antivirals by Wyles, D., Lawitz, E., Mcnabb, B., Lu, J., Chang, S., Osinusi, A., Svarovskaia, E.S., Brainard, D., Pianko, S., Feld, J., Mo, H., Dvory-Sobol, H.

Get full text

Emergence and long-term persistence of NS3, NS5A, and NS5B resistance associated substitutions after treatment with direct-acting antivirals by Wyles, D., Lawitz, E., Mcnabb, B., Lu, J., Chang, S., Osinusi, A., Svarovskaia, E.S., Brainard, D., Pianko, S., Feld, J., Mo, H., Dvory-Sobol, H.

Get full text

THU-220 - Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks by Gane, E., Svarovskaia, E.S., Dvory-Sobol, H., Hyland, R.H., Stamm, L.M., Brainard, D.M., Miller, M.D., Mo, H., Schwabe, C., Stedman, C.A.

Get full text